Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ujalla Sheikh"'
Autor:
Prosper Igboeli, Abdeljabar El Andaloussi, Ujalla Sheikh, Hajra Takala, Amro ElSharoud, Ashley McHugh, Larisa Gavrilova-Jordan, Steven Levy, Ayman Al-Hendy
Publikováno v:
Journal of Medical Case Reports, Vol 14, Iss 1, Pp 1-11 (2020)
Abstract Background Premature ovarian failure is a relatively common condition that affects 1–3% of adult women. Premature ovarian failure occurs when there is loss of ovarian function in women younger than 40 years of age. The causes are mostly ia
Externí odkaz:
https://doaj.org/article/41448ab6384d409c92848204a48d414e
Publikováno v:
Biomedicines, Vol 6, Iss 4, p 102 (2018)
Premature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before the age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g.; anticancer treatment, genet
Externí odkaz:
https://doaj.org/article/fc0ec12e03fb48b3b2a7b1447d49c28c
Autor:
Andre Kajdacsy-Balla, Adam B. Murphy, Adrian Rosenberg, Ujalla Sheikh, Roohollah Sharifi, Pooja Gogana, Virgilia Macias, Rick A. Kittles, Oluwarotimi Nettey
Publikováno v:
Cancer Causes Control
PURPOSE: To investigate the correlation between serum 25 hydroxyvitamin D, prostatic 25 hydroxyvitamin D, and serum 1,25 dihydroxyvitamin D, and their respective associations with prostatic tumor proliferation at the time of radical prostatectomy. ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677753d61658b7d2a1c6245d9678cede
https://doi.org/10.1007/s10552-019-1128-2
https://doi.org/10.1007/s10552-019-1128-2
Publikováno v:
Gastroenterology. 162:S-1384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ec8adc21dfe599de2c9ef3deb5f1bd6
https://doi.org/10.1016/s0016-5085(22)64040-x
https://doi.org/10.1016/s0016-5085(22)64040-x
Autor:
Abdeljabar El Andaloussi, Ayman Al-Hendy, Larisa Gavrilova-Jordan, Prosper Igboeli, Hajra Takala, Ashley McHugh, Steven Levy, Amro Elsharoud, Ujalla Sheikh
Publikováno v:
Journal of Medical Case Reports
Journal of Medical Case Reports, Vol 14, Iss 1, Pp 1-11 (2020)
Journal of Medical Case Reports, Vol 14, Iss 1, Pp 1-11 (2020)
Background Premature ovarian failure is a relatively common condition that affects 1–3% of adult women. Premature ovarian failure occurs when there is loss of ovarian function in women younger than 40 years of age. The causes are mostly iatrogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af78942890989bc38b9d63095b8a71d6
https://doi.org/10.1186/s13256-020-02426-5
https://doi.org/10.1186/s13256-020-02426-5
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 19(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6898fb3d64dba107ab627dd243cd456
https://pubmed.ncbi.nlm.nih.gov/32272246
https://pubmed.ncbi.nlm.nih.gov/32272246
Publikováno v:
Journal of the American Society of Cytopathology. 10:S54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f9590c6d9a4f1093ba1e24d07a9762
https://doi.org/10.1016/j.jasc.2021.07.091
https://doi.org/10.1016/j.jasc.2021.07.091
Publikováno v:
Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances ISBN: 9781493934249
Breast carcinomas with neuroendocrine features (NEC) have only been recently recognized as a separate diagnostic entity by the World Health Organization classification. This category of tumors encompasses neuroendocrine tumor, well differentiated; ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::474aad8be8126fc17af3c205b8cf6ab3
https://doi.org/10.1007/978-1-4939-3426-3_10
https://doi.org/10.1007/978-1-4939-3426-3_10
Publikováno v:
Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances ISBN: 9781493934249
In recent years, a number of therapeutic agents have been tested in clinical trials and approved for neuroendocrine tumors (NETs), including an antiangiogenic agent (sunitinib) and an mTOR inhibitor (everolimus). Despite this clinical success, we sti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb63aa5b5ea9a973f0a36cf5ce01bad8
https://doi.org/10.1007/978-1-4939-3426-3_25
https://doi.org/10.1007/978-1-4939-3426-3_25